J BUON. 2021 Jul-Aug;26(4):1226-1230.
ABSTRACT
PURPOSE: The purpose of this study was to explore the clinical diagnostic value of combined detection of multiple tumor markers (CEA, CA242, CA19.9 and CA125) and blood lipid indexes in colorectal cancer, and to analyze their predictive effect on adverse reactions after chemotherapy.
METHODS: The clinical data of 35 patients with colorectal adenoma, 64 patients with colorectal cancer I-II and 29 patients with colorectal cancer III-IV were retrospectively analyzed. All the patients were admitted to our hospital from April 2017 to December 2019. The antigen level of tumor markers and the plasma level in patients were detected before surgery to compare the expression difference of different tumor types. The Youden index, sensitivity and specificity of the four tumor markers were compared when used alone or in combination.
RESULTS: After one year of follow-up, the levels of tumor markers in patients with tumor metastasis were significantly higher than those in patients without tumor metastasis, with a statistically significant difference (p<0.001). The combination of four markers was better than single tumor marker in the evaluation indexes of diagnostic effect. The combined detection of multiple tumor markers and blood lipid indexes was correlated with the occurrence of five adverse reactions of chemotherapy (p<0.05).
CONCLUSION: The detection of multiple tumor markers and blood lipid indexes can effectively improve the diagnosis of colorectal cancer and enhance the predictive effect on adverse reactions of chemotherapy. HDL, LDL and ApoAI indexes can be used to diagnose the benign and malignant properties of tumors, and determine the clinical stages.
PMID:34564974
